AstraZeneca may have exited the COVID-19 vaccine market, but it is still hoping to protect vulnerable patients with its antibody sipavibart for pre-exposure prophylaxis (PrEP).

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, playing catch-up with rival MSD.

Review the current valuation for AstraZeneca PLC ADR (AZN:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

Here’s a map of the wildfire smoke and a look at the air quality warnings and advisories in place across Canada.